Monday, August 17, 2020

LARIMAR THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q) share with twitter share with LinkedIn share with facebook

MarketScreener; 08/14/2020.
CTI-1601 is currently being evaluated in Phase 1 clinical trials in patients with Friedreich's Ataxia. We have received orphan drug status, fast track designation and rare pediatric disease designation, from the U.S. Food and Drug Administration (the "FDA"), for CTI­1601. In addition, the European Medicines Agency ("EMA") Committee for Orphan Medicinal Products ("COMP") issued a positive opinion on the Company's application for orphan drug designation for CTI-1601. The receipt of such designations or positive opinions may not result in a faster development process, review or approval compared to products considered for approval under conventional FDA or EMA procedures and does not assure ultimate approval by the FDA or EMA.

Larimar Therapeutics (LRMR) Investor Presentation - Slideshow

Seeking Alpha Aug. 13, 2020 6:05 PM ET | About: Larimar Therapeutics, Inc. (LRMR)

About CTI-1601